NCT00025597 · CITED IN SOURCE DOCUMENTS

Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma.

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2013-09-17

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving a chemotherapy drug before surgery may shrink the tumor so that it can be removed during surgery. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by surgery in treating infants who have newly diagnosed neuroblastoma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

No posted result sections were captured. Registered plans do not establish that a treatment works.

Who could take part

eligibility Criteria: DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed newly diagnosed stage II or III neuroblastoma or ganglioneuroblastoma * Unresectable disease * No MYCN amplification (i.e., fewer than 10 copies) * No metastases to bone marrow * No radiological bone lesions in skeleton PATIENT CHARACTERISTICS: Age: * Under 12 months at diagnosis Performance status: * Not specified Life expectancy: * Not specified Hematopoietic: * Not specified Hepatic: * No evidence of liver disease by ultrasound Renal: * Not specified PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * Not specified Endocrine therapy * Not specified Radiotherapy * Not specified Surgery * Not specified
healthy Volunteers: false
maximum Age: 1 Year
sex: ALL
std Ages: CHILD

Treatment arms and interventions

interventions

name
carboplatin
type
DRUG
name
cyclophosphamide
type
DRUG
name
doxorubicin hydrochloride
type
DRUG
name
etoposide
type
DRUG
name
vincristine sulfate
type
DRUG
name
conventional surgery
type
PROCEDURE

Study design

primary Purpose: TREATMENT

Enrollment

Source null

Registered outcome plans (not posted results)

Full study description

brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving a chemotherapy drug before surgery may shrink the tumor so that it can be removed during surgery. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by surgery in treating infants who have newly diagnosed neuroblastoma.
detailed Description: OBJECTIVES: * Determine the survival and morbidity of infants with newly diagnosed stage II or III unresectable neuroblastoma without MYCN amplification treated with vincristine and cyclophosphamide, etoposide and carboplatin, and cyclophosphamide, doxorubicin, and vincristine followed by surgery. * Determine whether deletion of chromosome 1p or diploidy/tetraploidy are prognostic factors in these patients. * Determine whether there are other prognostic criteria that could be used in future therapeutic stratification of these patients. OUTLINE: This is a multicenter study. Patients are stratified according to symptomatic spinal cord involvement (yes vs no). Patients without evidence of symptomatic spinal cord compression receive vincristine IV on day 1 and cyclophosphamide IV on days 1-5. Treatment repeats every 14 days for 2 courses. Patients eligible for surgery undergo surgical resection and then are removed from the study. Patients ineligible for surgery after 2 courses of initial chemotherapy, but with at least 25% response to initial chemotherapy, receive 2 additional courses of vincristine and cyclophosphamide. Patients eligible for surgery undergo surgical resection and then are removed from the study. Patients ineligible for surgery after 2 additional courses of initial chemotherapy or with disease progression receive etoposide IV over 2 hours and carboplatin IV over 1 hour on days 1-3. Treatment repeats every 21 days for 2 courses. Patients eligible for surgery undergo surgical resection and then are removed from the study. Patients who remain ineligible for surgery or with disease progression after etoposide and carboplatin receive cyclophosphamide IV over 1 hour on days 1-5, doxorubicin IV over 6 hours on days 4 and 5, and vincristine IV on days 1 and 5. Treatment repeats every 21 days for 2 courses. Patients then undergo surgical resection or biopsy. Patients with symptomatic spinal cord compression receive initial treatment with etoposide and carboplatin as above. Patients with improved symptoms and resectable disease after initial chemotherapy undergo surgical resection or biopsy. Patients who remain ineligible for surgery or with no improvement in symptoms after initial chemotherapy receive cyclophosphamide, doxorubicin, and vincristine as above. Patients then undergo surgical resection or biopsy. Patients are followed within 6 months and then annually for 5 years. PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study within 4 years.

Source references

references

citation
Rubie H, De Bernardi B, Gerrard M, Canete A, Ladenstein R, Couturier J, Ambros P, Munzer C, Pearson AD, Garaventa A, Brock P, Castel V, Valteau-Couanet D, Holmes K, Di Cataldo A, Brichard B, Mosseri V, Marquez C, Plantaz D, Boni L, Michon J. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. J Clin Oncol. 2011 Feb 1;29(4):449-55. doi: 10.1200/JCO.2010.29.5196. Epub 2010 Dec 20.
pmid
21172879
type
RESULT

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-7ad944f6deaf1f5cd6122126
edge id
nct-edge-7d9b13daa399a836edc9
requested nct id
NCT00025597
primary nct id
NCT00025597
source kind
nci_explicit_reference_or_link
source url
https://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq
source record id
Source null
source file sha256
308a08f515ba694b00db3851eb2531e1ed582dada1d1a75d9bb7c00853441821
payload sha256
5be626d702c41299b8fdf85333e6db8bc326938d8016b294a40d3c8af1cae65c
payload
clinical indication matching status
not_inferred
end exclusive
true
id
nct-edge-7d9b13daa399a836edc9
link basis
explicit_NCT_identifier_in_acquired_source
nct id
NCT00025597
occurrences
context exact
></ul></div></li><li>Moderate-dose chemotherapy has been shown to be effective in the prospective Infant Neuroblastoma European Study (<a href="/clinicaltrials/NCT00025597">EURO-INF-NB-STUDY-1999-99.1</a>). About one-half of the infants with unresectable, nonmetastatic neuroblastoma and no <em class="gene-name">MYCN</em> amplific
end
362790
exact text
NCT00025597
start
362779
offset unit
unicode_code_points
source file
/tmp/cancer-full-research/nci/raw/d023d406c02e860e22.html
source file sha256
308a08f515ba694b00db3851eb2531e1ed582dada1d1a75d9bb7c00853441821
source json pointer
Source null
source kind
nci_explicit_reference_or_link
source record id
Source null
source retrieved at
2026-09-09T23:22:09.227808+00:00
source string basis
UTF-8_text_with_universal_newline_translation
source string sha256
5a0bcb41a33182c1bb316ea92b74ca10701add33aec3077a54a565e6d80cbf53
source title
Neuroblastoma Treatment (PDQ®)–Health Professional Version
source update dates
context
Updated: April 28, 2025
datetime
2025-04-28T12:00:00Z
display
April 28, 2025
source url
https://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq

Preserved source evidence · Not medical advice